IP Library › Granted Patent US 12,686,702
Granted Patent B2
US 12,686,702 · App. 17/978,791 · Granted Jul 21, 2026

Methods for purifying antibodies

Inventors: Andre C. Dumetz (King of Prussia, PA); Kent E. Goklen (King of Prussia, PA); Nicholas E. Levy (King of Prussia, PA); Jessica Rachel Molek (King of Prussia, PA); Andrew S. Thomson (Collegeville, PA); Kenneth G. Yancey (Wayne, PA)
Assignee: GlaxoSmithKline Intellectual Property Development Limited
C07K1/22B01D15/3809B01D15/424C07K16/065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,686,702
App. No.
17/978,791
Granted
Jul 21, 2026
Kind
B2
Abstract

The present invention relates to a method of purifying a recombinant polypeptide from Host Cell Proteins (HCP), the method comprising: (a) applying a solution comprising the recombinant polypeptide and HCP to a superantigen chromatography solid support, (b) washing the superantigen chromatography solid support with a wash buffer comprising caprylate and arginine; and (c) eluting the recombinant polypeptide from the superantigen chromatography solid support.

Claims (19)

1 . A method of purifying a recombinant polypeptide from Host Cell Proteins (HCP), the method comprising:

(a) applying a solution comprising the recombinant polypeptide and HCP to a superantigen chromatography solid support,

(b) washing the superantigen chromatography solid support with a wash buffer comprising about 100 mM to about 300 mM caprylate, about 0.75 M to about 1.5 M arginine, about 1 mM to about 500 mM Tris base and about 1 mM to about 500 mM acetic acid, wherein the pH of the wash buffer is about 7.5 to about 8.5; and

(c) eluting the recombinant polypeptide from the superantigen chromatography solid support,

wherein the superantigen chromatography solid support is a chromatography solid support having a superantigen immobilized therein, and wherein the superantigen is selected from the group consisting of Protein A, Protein G, and Protein L.

2 . The method according to claim 1 , wherein the wash buffer comprises about 100 mM caprylate.

3 . The method according to claim 1 , wherein the wash buffer comprises about 1.5 M about 1.1 M arginine.

4 . The method according to claim 1 , wherein the wash buffer further comprises about 0.5 M to about 1 M lysine.

5 . The method according to claim 1 , wherein the eluted recombinant polypeptide contains less than about 2% fragmented recombinant polypeptide.

6 . The method according to claim 1 , wherein the HCP is derived from a mammalian cell.

7 . The method according to claim 1 , wherein the HCP is phospholipase B-Like 2 protein.

8 . The method according to claim 1 , wherein the HCP is cathepsin L.

9 . The method according to claim 8 , wherein the purification of the recombinant polypeptide from cathepsin L is measured by a reduced cathepsin L activity in the eluate of step (c).

10 . The method according to claim 1 , wherein the recombinant polypeptide is a monoclonal antibody (mAb).

11 . The method according to claim 10 , wherein the mAb is an IgG1, or an IgG4.

12 . The method according to claim 1 , wherein the wash buffer does not contain sodium chloride.

13 . The method according to claim 1 , wherein the superantigen is Protein A.

14 . The method according to claim 1 , wherein after step (c) the amount of HCP is less than about 200 ng HCP/mg product.

15 . The method according to claim 1 , wherein the wash buffer comprises 55 mM Tris base, 45 mM acetic acid, 100 mM sodium caprylate, and 1.1 M arginine, and wherein the pH of the wash buffer is pH 7.5.

Assignments (4)
CHANGE OF ADDRESS Recorded Oct 8, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073032/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2024
From: GOKLEN, KENT E.; MOLEK, JESSICA RACHEL; DUMETZ, ANDRE; LEVY, NICHOLAS E.; THOMSON, ANDREW S.; YANCEY, KENNETH G.
To: GLAXOSMITHKLINE LLC
Reel/Frame 069050/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2024
From: GLAXOSMITHKLINE LLC
To: GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED
Reel/Frame 069050/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2024
From: GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 069050/0885 →
Continuity (3)
Continuation 16330588 · Sep 6, 2017
Provisional Application 62384240 · Sep 7, 2016
Related Publication 20230046182A1 · Feb 16, 2023
References Cited (53)
US 5429746A · Shadle et al. · 1995 [cited by applicant]
US 10259842B2 · Gruber et al. · 2019 [cited by applicant]
US 10676503B2 · Goklen et al. · 2020 [cited by applicant]
US 11530238B2 · Dumetz · 2022 [cited by examiner]
US 12358945B2 · Goklen et al. · 2025 [cited by applicant]
US 20030152966A1 · Alred et al. · 2003 [cited by applicant]
US 20080167450A1 · Pan · 2008 [cited by applicant]
US 20080182979A1 · Lihme et al. · 2008 [cited by applicant]
US 20120122759A1 · Brown et al. · 2012 [cited by applicant]
US 20160108084A1 · Gruber et al. · 2016 [cited by applicant]
US 20160319012A1 · Yu et al. · 2016 [cited by applicant]
CN 1922207A · 2007 [cited by applicant]
CN 101454025A · 2009 [cited by applicant]
CN 105188872A · 2015 [cited by applicant]
JP 2009522580A · 2009 [cited by applicant]
JP 2010502737A · 2010 [cited by applicant]
JP 2016519145A · 2016 [cited by applicant]
JP 2016519052A · 2016 [cited by applicant]
JP 7058272B2 · 2022 [cited by applicant]
WO 03102208A2 · 2003 [cited by applicant]
WO 2005082937A2 · 2005 [cited by applicant]
WO 2005113604A2 · 2005 [cited by applicant]
WO 2007081851A2 · 2007 [cited by applicant]
WO 2007109163A2 · 2007 [cited by applicant]
WO 2007117490A2 · 2007 [cited by applicant]
WO 2008031020A2 · 2008 [cited by applicant]
WO 2012135415A1 · 2012 [cited by applicant]
WO 2014141150A1 · 2014 [cited by applicant]
WO 2014186350A1 · 2014 [cited by applicant]
WO 2015038888A1 · 2015 [cited by applicant]
Ishihara et al. Improving impurities clearance by amino acids addition to buffer solutions for chromatographic purifications of monoclonal antibodies. J. Chromatogr. B 995-996 (2015) 107-114. (Year: 2015). [cited by examiner]
Brodsky, Yan, et al., “Caprylic acid precipitation method for impurity reduction: an alternative to conventional chromatography for monoclonal antibody purification”, Biotechnology and Bioengineering, vol. 109, No. 10, … [cited by applicant]
Chhatre et al., “Evaluation of a novel agarose-based synthetic ligand adsorbent for the recovery of antibodies from ovine serum”, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, vol. 860, No. 2, pp. 209-217. [cited by applicant]
Chollangi, S. et al., “Development of Robust Antibody Purification by Optimizing Protein-A Chromatography in Combination With Precipitated Methodologies”, Biotechnology and Bioengineering (2015), vol. 112, No. 11, pp. 2… [cited by applicant]
Monie, Elin “Evaluation of the 96-well format for screening of chromatographic buffer conditions” Master's degree project, 58 pages, 2006. [cited by applicant]
Newcombe et al. “Optimised affinity purification of polyclonal antibodies from hyper immunised ovine serum using a synthetic Protein A adsorbent, MAbsorbent A2P”, J. of Chromatography B, vol. 814, pp. 209-215, 2005. [cited by applicant]
Nilson, B. H. K., et al., “Purification of antibodies using protein L-binding framework structures in the light chain variable domain”, Journal of Immunological Methods, vol. 164, No. 1, Aug. 26, 1993, pp. 33-40. [cited by applicant]
Tong, Hong-Fei, et al., “Caprylate as the albumin-selective modifier to improve IgG purification with hydrophobic charge-induction chromatography”, Journal of Chromatography, A Apr. 12, 2013, vol. 1285, Feb. 15, 2013, p… [cited by applicant]
Li, Heping, “The Production Principle and Technology of Fine Chemicals”, Henan Science and Technology Press, p. 336, Sep. 30, 1994, 4 pages (C1). [cited by applicant]
“Clinical Medical Examination”, Fuzhou Army General Hospital, Shanghai Science and Technology Press, p. 253, Apr. 30, 1978, 7 pages (C2). [cited by applicant]
Aboulaich et al., “A Novel Approach to Monitor Clearance of Host Cell Proteins Associated with Monoclonal Antibodies”, Biotechnology Progress, vol. 30, No. 5, pp. 1114-1124 (2014). [cited by applicant]
Levy et al., “Development and characterization of a protein A capture step for improved impurity clearance”, Process Development, Biopharmaceutical Development, King of Prussia, PA, Washes—ACS BIOT Poster, Denver, 2015,… [cited by applicant]
Anonymous: “Albumin in Cell Culture,” Sigma-Aldrich, Oct. 26, 2008, pp. 1-2, XP055751730. [cited by applicant]
Chhatre S., et al., “Purification of Antibodies Using the Synthetic Affinity Ligand Absorbent MAbsorbent A2P,” Nature Protocols, 2007, vol. 2(7), pp. 1763-1769. [cited by applicant]
Fraser J.D., et al., “The Bacterial Superantigen and Superantigen-like Proteins,” Immunological Reviews, Oct. 2008, vol. 225, pp. 226-243. [cited by applicant]
Haiou Y., et al., “Purification of Human Immunoglobulin G via Fc-specific Small Peptide Ligand Affinity Chromatography,” Journal of chromatography, Feb. 2009, vol. 1216(6), pp. 910-918. [cited by applicant]
Henry K.A., et al., “A Rational Engineering Strategy for Designing Protein a-binding Camelid Single-domain Antibodies,” PLos One, Sep. 2016, vol. 11(9), pp. 1-18. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2017/055374, mailed Mar. 21, 2019, 12 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2014/059755, mailed Jul. 9, 2014, 12 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2017/055374, mailed Jan. 29, 2018, 15 Pages. [cited by applicant]
Le Merdy S., “Selection of Clarification Methods for Improved Downstream Performance and Economics,” Bioprocessing Journal, Oct. 2015, vol. 14(3), pp. 50-55. [cited by applicant]
Liu Z., et al., “Effects of Peptide Density and Elution pH on Affinity Chromatographic Purification of Human Immunoglobulins A and M,” Journal of Chromatography A, Nov. 2011, vol. 1218(46), pp. 8344-8352. [cited by applicant]
Naik A.D., et al., “Performance of Hexamer Peptide Ligands for Affinity Purification of Immunoglobulin G from Commercial Cell Culture Media,” Journal of Chromatography A, 2011, vol. 1218, pp. 1691-1700. [cited by applicant]